Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from co-pay assistance constraints.

Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for EMPAVELI® boosts future prospects.

FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits.

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.